ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 108 filers reported holding ALBIREO PHARMA INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $221,756 | -2.3% | 7,434 | -23.7% | 0.00% | – |
| Q4 2021 | $227,000 | -24.3% | 9,743 | +1.5% | 0.00% | – |
| Q3 2021 | $300,000 | -15.7% | 9,601 | -5.3% | 0.00% | – |
| Q2 2021 | $356,000 | -2.7% | 10,133 | -2.3% | 0.00% | – |
| Q1 2021 | $366,000 | -6.6% | 10,373 | -0.7% | 0.00% | – |
| Q4 2020 | $392,000 | +45.7% | 10,451 | +29.5% | 0.00% | – |
| Q3 2020 | $269,000 | +18.5% | 8,072 | -3.1% | 0.00% | – |
| Q2 2020 | $227,000 | -1.3% | 8,329 | +16.9% | 0.00% | – |
| Q2 2019 | $230,000 | -14.5% | 7,125 | -5.9% | 0.00% | – |
| Q2 2018 | $269,000 | +2345.5% | 7,572 | +2057.3% | 0.00% | – |
| Q1 2018 | $11,000 | +22.2% | 351 | -0.3% | 0.00% | – |
| Q4 2017 | $9,000 | +28.6% | 352 | +1.1% | 0.00% | – |
| Q3 2017 | $7,000 | +600.0% | 348 | +582.4% | 0.00% | – |
| Q2 2017 | $1,000 | – | 51 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |